Research programme: fms-like tyrosine kinase 3/cyclin dependent kinase 4 inhibitors - Amgen

Drug Profile

Research programme: fms-like tyrosine kinase 3/cyclin dependent kinase 4 inhibitors - Amgen

Alternative Names: AM-5992; flt3/CDK4 dual kinase inhibitor - Amgen

Latest Information Update: 31 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 20 Oct 2013 Pharmacodynamics data for AMG 5992 from a preclinical trial in Acute myeloid leukaemia presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2013)
  • 20 Oct 2013 Preclinical trials in Acute myeloid leukaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top